In ₹ Crore except Per Share Latest Annual | SHILPAMED FY26 | NATCOPHARM FY26 | SPARC FY26 | STAR FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 75.80× | 10.34× | ◆ 4.11× | 20.07× | 10.34× +633% | |
| P/B | 7.12× | ◆ 1.59× | 4.77× | 3.54× | 3.54× +101% | |
| EV/EBITDA | 43.85× | 10.15× | ◆ 4.34× | 13.66× | 10.15× +332% | |
| Market Cap | ₹18,445 Cr | ₹14,657 Cr | ₹6,386 Cr | ₹11,162 Cr | ₹11,162 Cr +65% | |
| Growth | ||||||
| Revenue CAGR 3Y | 13.59% | 14.64% | ◆ 95.98% | 9.62% | 14.64% -7% | |
| Revenue CAGR 5Y | 11.30% | ◆ 14.72% | — | 7.94% | 11.33% -0% | |
| Net Income CAGR 3Y | — | 25.64% | — | — | 25.64% | |
| Revenue YoY (latest Q) | 44.90% | -44.68% | ◆ 314.11% | 13.01% | 13.01% +245% | |
| Net Income YoY (latest Q) | ◆ 115.16% | -57.01% | 59.94% | 56.73% | 56.73% +103% | |
| Profitability | ||||||
| EBITDA Margin | 28.25% | 35.22% | ◆ 85.08% | 19.04% | 35.22% -20% | |
| Net Income Margin | 15.81% | 34.78% | ◆ 82.65% | 11.82% | 34.78% -55% | |
| Return on Common Equity | 9.39% | 15.38% | ◆ 116.20% | 17.66% | 17.66% -47% | |
| Return on Capital Employed | 11.02% | 13.09% | ◆ 112.12% | 17.93% | 17.93% -39% | |
| Return on Assets | 6.57% | 12.81% | ◆ 71.55% | 8.29% | 12.81% -49% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.25× | ◆ 0.08× | 0.42× | 0.53× | 0.42× -40% | |
| Interest Coverage | 5.36× | 33.51× | ◆ 46.54× | 4.05× | 33.51× -84% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹1,539 Cr | ₹4,078 Cr | ₹1,879 Cr | ₹4,859 Cr | ₹4,078 Cr -62% | |
| Net Income | ₹243 Cr | ₹1,419 Cr | ₹1,553 Cr | ₹575 Cr | ₹1,419 Cr -83% | |
| Total Assets | ₹3,706 Cr | ₹11,074 Cr | ₹2,171 Cr | ₹6,927 Cr | ₹6,927 Cr -47% | |
| EPS | ₹12.44 | ₹79.2 | ₹47.86 | ₹60.34 | ₹60.34 -79% | |
| Book Value per Share | ₹132.47 | ₹515.15 | ₹41.26 | ₹341.68 | ₹341.68 -61% | |